Arcutis Biotherapeutics
ARQT24.4901.32% ( +0.320 )
Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead...
- Open
- 23.910
- High
- 24.570
- Low
- 23.370
- Prev. Close
- 24.170
- Volume
- 2.61M
- Turnover
- 62.74M
- Avg Price
- 24.078
- Bid/Ask Ratio
- --
- Amplitude
- 4.96%
- 52wk High
- 31.770
- Volume Ratio
- 2.26
- Turnover Ratio
- 2.78%
- 52wk Low
- 19.295
- Float Mkt Cap
- 2.30B
- Market CapUSD
- 3.08B
- P/ETTM
- 107.93
- P/EDynamic
- 414.40
- P/EStatic
- --
- EPSTTM
- 0.227
- EPSDynamic
- 0.0591
- EPSStatic
- --
- BVPS
- 1.75
- P/B
- 13.96
- Circulating Supply
- 93.82M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 125.69M
- Min lot size
- 1
- Currency
- USD
Arcutis Biotherapeutics Analyst Rating
View moreForecast & Rating
Oct 8, 2026Price forecast
$37.0051.08%
Forecast & RatingBuy
7analysts
- Strong buy57.14%
- Buy28.57%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan ·
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award | ARQT Stock News
- GlobeNewswire ·
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Unusual Whales ·
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
- Weekly Review ·
Weekly Recap | ARQT.US +6.26%, consensus target above spot
- PUBT ·
Arcutis EVP, Chief Legal Officer Masaru Matsuda disposes of 3,674 common shares for $91,753.31
- Global Report ·
Beyond the Hype: How Biotech Navigates the Harsh Realities of 2026
